Fall Summit Focused on Specialty Pharma and Rare Disease Companies
- September 23-24, 2019
Both days will feature 1on1 meetings with a select group companies focused on specialty pharma and orphan and rare disease. Investors will have the opportunity to meet with management teams to discuss in detail key therapeutic programs in development and recent corporate updates.
To access information for the Fall Summit, please enter your password. Your password can be found in the email invitation that was sent to you.
Conferences are only open to established institutional clients of Oppenheimer & Co. Inc. For more information, please contact your Oppenheimer & Co. Inc. institutional sales representative.
Log In For Details
Thank you to all of our attendees, organizers, and thought leaders who made this conference a success.
Kenneth R. Hoffman, MD, MPH, is a Medical Oncologist in private practice in Teaneck, New Jersey (1984-present). Dr. Hoffman has been practicing for the past 34 years specializing in hematology, immunology and oncology. His clinical focus is breast cancer (1/3 of practice), lung cancer (1/3 of practice), and leukemia/lymphoma (1/3 of practice). Dr. Hoffman is double board-certified in Internal Medicine and Medical Oncology. He brings a unique opinion to the study of cancer with his background in Public Health. Currently Dr. Hoffman is a Clinical Professor of Medical Oncology and Preventive Medicine at Rutgers Medical School and also teaches in the SOPH. As a cancer epidemiologist his expertise is in the evaluation of clinical trial as well as testing issues and in quality assurance through appropriate pathway development.
Jonathan D. Field, MD, is the Director of Pediatric Allergy at Beth Israel Medical Center in New York (2013 - Present). He is part of the division of Allergy and Immunology at ProHealthcare, a multispecialty practice in the Greater New York area. He is also an instructor at Mount Sinai Hospital. He was previously the Director of the Allergy and Immunology Clinic at NYU Medical Center/Bellevue. His interests include adult and pediatric asthma, sinus disease and urticaria (hives) as well as immunologic disease. He has been treating hereditary angioedema (HAE) patients in academic and private settings since 2000. He has also done research in HIV vaccine production and was a principal investigator in studies using monoclonal anti-IgE antibodies in the treatment of asthma and allergic disease. He has particular experience in hypersensitivity reactions and anaphylaxis from monoclonal anti IgE products and collagenase.
Eliot Brinton, MD is Director of Atherometabolic Research at the Utah Foundation for Biomedical Research, President of the American Board of Clinical Lipidology, and Chair of the Clinical Lipidology Committee of the American Heart Association. He is an Associate Editor of the Journal of Clinical Lipidology and the Journal of Obesity. Dr. Brinton’s areas of clinical expertise include dyslipidemia, diabetes, obesity and insulin resistance, and atherosclerosis, and his research interests include hypertriglyceridemia, hypercholesterolemia, diabetes, obesity, postmenopausal estrogen replacement, insulin sensitivity, and mechanisms of HDL metabolism. He has authored over 100 articles in journals including Science, the New England Journal of Medicine, JAMA, Circulation, and the Journal of Clinical Investigation.
Kevin C Maki, PhD is President and Chief Scientist for the Midwest Biomedical Research/Center for Metabolic and Cardiovascular Health in Chicago, IL. He specializes in the design and conduct of clinical studies in human metabolism and chronic disease risk factor management. Dr Maki also holds an Adjunct Faculty position teaching Biostatistics and Applied Epidemiology at DePaul University. He is a Fellow of the National Lipid Association, The Obesity Society and the American College of Nutrition, as well as a certified Clinical Lipid Specialist and is current President of the Board of Governors for the Accreditation Council for Clinical Lipidology. He lectures nationally and internationally on the roles of genetics and lifestyle in the development of cardiovascular disease and type 2 diabetes mellitus, and has participated in more than 300 clinical trials and observational studies related to cardiometabolic disease prevention and management. Dr. Maki has published over 250 peer reviewed papers in leading scientific and medical journals.
James Valentine, JD, MHS, is an associate at Hyman, Phelps & McNamara, P.C. where he assists medical product industry and patient advocacy organization clients in a wide range of regulatory matters, including new drug and biologic development and approval issues. Mr. Valentine has been central to the transition of the FDA Patient-Focused Drug Development (PFDD) program to externally-led meetings, having helped plan and moderated the majority of those, and is also working on novel methodologies for capturing patient experience data. Mr. Valentine has also authored an analysis cataloguing FDA's flexibility in assessing efficacy in the approval of drugs for rare, or orphan, conditions.
Event StatisticsAs of 9/20/2019
Specialty Pharma Companies
Rare Disease Companies